JP received his undergraduate degree in aeronautical engineering from the Massachusetts Institute of Technology and worked at the Air Force National Laboratory, Lincoln Laboratories. He holds both law and mechanical/materials engineering graduate degrees from Duke University.
Chairman, Founder, Principal Investor and
Chief Science & Strategy Officer of electroCore
JP trained as a patent attorney in New York and is the author of a treatise on international intellectual property law. Along with fellow investor and board member Dr. Thomas Errico, JP has founded a number of medical device companies, including Fastenetix, K2 Medical, AD-4 Pharma, E2, and SpineCore. Products conceived by these companies have generated more than $12 billion in sales to date. He served as the CEO of SpineCore from the inception of the company through its sale to Stryker in July 2004.
JP is a named inventor on more than 125 issued US patents and is a named inventor on more than 100 pending US applications. Additional patents and patent applications outside the US on which he is a named inventor number greater than 200. In addition to his current role as CSSO, he continues also to make significant inventive contributions in all aspects of the company’s key patent portfolios, along with the clinical and market validations of the company’s products and their indications.
Thomas J. Errico, MD
Dr. Errico is a graduate of the New Jersey College of Medicine. After completing a residency in orthopedic surgery, he completed a yearlong fellowship in spinal surgery in Toronto with Dr. John Kostuik. After his fellowship, Dr. Errico accepted a joint position in the faculties of both Orthopedic Surgery and Neurosurgery at the New York University Medical School. Now a tenured professor in both departments, Dr. Errico is serving as the Chief of Spine Service for both New York University and the Hospital for Joint Diseases. He is an original member of the North American Spine Society and served as that society’s President in 2004-5.
Founder and Principal Investor
Along with J.P. Errico, he founded several medical device companies, and according to the MedicineLodge 2001 Spinal Implant Intellectual Property Report, Dr. Errico is the most prolific surgeon inventor in the field of spine orthopedics. Dr. Errico has been identified as one of the 10 best orthopedic surgeons in the United States. Dr. Errico served on the Board of Directors of SpineCore from its inception to sale. Dr. Errico serves as a primary contributor and advisor to electroCore for the development of the company’s products and their indications.
Jeff Vinik is the Owner and Chairman of the Tampa Bay Lightning of the National Hockey League and serves on the NHL Board of Governors and Executive Committee. In addition, Jeff manages various family investments, oversees the Vinik Family Foundation with his wife, Penny, and is part owner, with Cascade Investment, of Strategic Property Partners, a real estate entity undertaking a $3 billion mixed use development project to revitalize downtown Tampa.
Jeff began his career in the investment management business with Fidelity Investments in 1986. From 1992-1996, Jeff ran the Fidelity Magellan Fund, the world’s largest mutual fund at the time, and was twice named “Portfolio Manager of the Year,” first by Morningstar in 1993 and then by Mutual Fund Magazine in 1995. In 1996, he left Fidelity to establish his own firm, Vinik Asset Management, a long-short equities hedge fund based in Boston where he grew assets under management from $800 million to $10 billion. Jeff closed his Boston firm in 2013 to focus on business and philanthropic interests in Tampa.
Jeff graduated from Duke University and earned his MBA from Harvard Business School. He has served on several non-profit boards, including United Way of Massachusetts Bay, Duke University, and the United States Figure Skating Foundation. The Viniks champion many charitable organizations, with emphasis on providing support for the education, entrepreneurship, and the arts. They established the Lightning Community Hero program in 2011 to provide funding and recognition to those improving the lives of individuals most in need. A $50,000 grant is given out at each home game to the community hero’s charity of choice.
Jeff and Penny reside in Tampa and have 4 children.
Kathryn Theofilos, Esquire
Kathryn is President of The Theo Group, a real estate investment and management company which has grown to over 300,000 square feet of commercial rental property and over 150 acres of prime development land located throughout Florida and in Tennessee. The Theo Group also holds in its portfolio significant investments in the Medical Device field, Health Care Field and Tech field. In 2004, The Theo Group’s innovative Health Facility, Oxygen Health and Wellness, was a nominee for the Leadership Award for Florida’s Small Business of the Year.
Founder and Principal Investor
Kathryn has a Bachelor of Arts in Economics and Business from the University of California at Los Angeles (UCLA) and graduated from Memphis State University with highest honors from the Cecil C. Humphreys School of Law where she was presented with the Outstanding Female Graduate Award. Kathryn was admitted into the practice of law in Tennessee and practiced as a Litigation Associate at Heiskell, Donelson the largest firm in Tennessee. In 1994, she was admitted into the practice of law in Florida, where she practiced defense litigation before taking over the reins at The Theo Group.
David Rubin, Ph.D.David is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. David has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. David holds board seats at OpGen, Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx. David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all Merck Research Laboratories (MRL) disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation, where he was CEO and President, and helped to build it into a pioneer bioinformatics products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies.
David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School, where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Trevor MoodyTrevor is President of TM strategic Advisors LLC, a management consultancy serving the boards, investors, and senior management of both emerging and established medical technology companies. Trevor brings significant experience with over 25 years in the development, commercialization and funding of innovative, growth-oriented medical technologies. He was most recently a General Partner at Frazier Healthcare Ventures, a leading healthcare venture capital and private equity investment firm with $1.8 billion under management. Trevor co-led the medical device team at Frazier and became known as an active and well-regarded investor. Prior to Frazier Healthcare, he was a Senior Consultant at The Wilkerson Group.
Trevor graduated from the Massachusetts Institute of Technology with a Masters of Science in Management (Sloan School) and the University of Southern Queensland, Australia with a Bachelor of Engineering. Trained as a Biomedical Engineer with an electrical focus, he held product development and product marketing roles at Telectronics Pacing Systems and Ventritex, both in the Cardiac Rhythm Management market.
Trevor is also Board Chair of Seattle BioMed, one of the largest independent, non-profit research institutes focused on diseases of the developing world.
Jim TullisJim founded Tullis Health Investors (“THI” or “Tullis-Dickerson & Co., Inc.”) in 1986 and has a career of over 40 years in health care investing.
Prior to establishing Tullis Health Investors in 1986, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, health care investment banking. During his tenure at Morgan Stanley, he received recognition fourteen times on the Institutional Investor All-Star list of Wall Street’s top securities analysts. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds, researching health care industry equities.
Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), LivHOME, Inc., SupplyPro, Inc., and electroCore, LLC.
Jim is married to Linda (Stanford, 1970) and lives in North Palm Beach, Florida. Jim and Linda have three married children and eight grandchildren. Jim is a member and former Board Member of Chief Executives Organization and a member of World President’s Organization.
Nick, who has served as Publicis Health CEO since May 2007, previously worked as the company’s Chief Operating Officer and joined in 2000 as President. His experience spans both the client and agency sides of the communications business.
Chief Executive Officer, Publicis Health
Prior to joining Publicis, Nick served as the Vice President of Marketing & Sales at EyeSys Technologies and Marketing Director at Roche. In addition to his current role, Nick leads key initiatives for the Coalition for Healthcare Communication, an industry trade association, and serves on the board of the American Heart Association of New York. He is also a passionate advocate for inclusion and gender parity. His leadership and continuous efforts have resulted in numerous accolades, such as multiple inclusions in PharmaVOICE’s “100 Most Inspiring People,” and the “Superhero of Heart and Stroke” Award from the American Heart Association.
In addition to his extensive relevant professional experience, Nick also has a Bachelor of Science in Neuroscience from the University of Rochester and a Masters of Business Administration from Loyola University Maryland.
Francis R. Amato
Prior to joining electroCore, Frank spent 22 years within the pharmaceutical industry, most recently as Vice President of the Specialty Commercial Operations Group, Global Human Health at Merck. Frank has extensive commercial experience through such previous roles as Executive Director, Global Business Operations, Schering-Plough; Business Unit Lead, Oncology, Ligand Pharmaceuticals; National Sales Director, Specialty Managed Markets, Pfizer Inc.; and National Sales Director Hospitals, Pharmacia Corporation. Frank joined The Upjohn Company in 1990 as a sales representative in NYC.
Chief Executive Officer, electroCore
Prior to joining the pharmaceutical industry, he was an Infantry Medic in the 82nd Airborne Division of the United States Army. Frank received his Executive MBA from Pepperdine University’s Graziadio School of Management in 2005 and an undergraduate degree in Political Science from St. John’s University in 1990.